PH22970A - Fused tricyclic derivatives of naphthyridinone, pyridone and quinoline and the corresponding thiones - Google Patents

Fused tricyclic derivatives of naphthyridinone, pyridone and quinoline and the corresponding thiones

Info

Publication number
PH22970A
PH22970A PH30728A PH30728A PH22970A PH 22970 A PH22970 A PH 22970A PH 30728 A PH30728 A PH 30728A PH 30728 A PH30728 A PH 30728A PH 22970 A PH22970 A PH 22970A
Authority
PH
Philippines
Prior art keywords
naphthyridinone
pyridone
quinoline
fused tricyclic
tricyclic derivatives
Prior art date
Application number
PH30728A
Other languages
English (en)
Inventor
David John Blythin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PH22970A publication Critical patent/PH22970A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PH30728A 1983-05-31 1984-05-29 Fused tricyclic derivatives of naphthyridinone, pyridone and quinoline and the corresponding thiones PH22970A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49958483A 1983-05-31 1983-05-31
US06/597,887 US4680298A (en) 1983-05-31 1984-04-09 Tricyclic anti-allergy and use as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
PH22970A true PH22970A (en) 1989-02-10

Family

ID=27053194

Family Applications (1)

Application Number Title Priority Date Filing Date
PH30728A PH22970A (en) 1983-05-31 1984-05-29 Fused tricyclic derivatives of naphthyridinone, pyridone and quinoline and the corresponding thiones

Country Status (14)

Country Link
US (1) US4680298A (fr)
EP (1) EP0127135B1 (fr)
JP (1) JPH0747590B2 (fr)
AU (1) AU559754B2 (fr)
CA (1) CA1251208A (fr)
DE (1) DE3483064D1 (fr)
DK (1) DK160557C (fr)
GB (1) GB2142013B (fr)
GR (1) GR81552B (fr)
HK (1) HK8092A (fr)
IL (1) IL71960A (fr)
NZ (1) NZ208310A (fr)
PH (1) PH22970A (fr)
SG (1) SG83890G (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596809A (en) * 1985-03-25 1986-06-24 Schering Corporation Substituted 1,8-naphthyridinones, useful as anti-allergic agents
DK127086A (da) * 1985-03-25 1986-09-26 Schering Corp Substituerede 1,8-naphthyridoner, fremgangsmaader til deres fremstilling og farmaceutiske kompositioner, der indeholder disse forbindelser
US5116840A (en) * 1985-06-13 1992-05-26 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4988705A (en) * 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
PT82752B (pt) 1985-06-13 1988-12-15 Schering Corp Processo para a preparacao de derivados policiclicos de quinolina, naftiridina e pirazinopiridina
US4810708A (en) * 1986-05-15 1989-03-07 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4801589A (en) * 1986-06-12 1989-01-31 Schering Corporation Method for suppressing the immune response
DE3669656D1 (de) * 1985-06-18 1990-04-26 Schering Corp Azanaphthalene enthaltende arzneimittelzusammensetzungen.
US4760073A (en) * 1986-04-11 1988-07-26 Schering Corporation Aryl-substituted naphthyridine and pyridopyrazine derivatives, useful as anti-allergic agents
US5011860A (en) * 1986-04-11 1991-04-30 Schering Corporation Aryl-substituted naphthyridine and pyridopyrazine derivatives and their use in treating hyperproliferative skin diseases
AU609389B2 (en) * 1986-04-11 1991-05-02 Schering Corporation Aryl-substituted naphthydridine and pyridopyrazine derivatives
US4882332A (en) * 1986-10-20 1989-11-21 Schering Corporation Immune suppression method employing arly-substituted naphthyridine and pyridopyrazine derivatives
US5037826A (en) * 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
US5045542A (en) * 1986-10-20 1991-09-03 Schering Corporation Immune suppression method employing aryl-substituted naphthyridine and pyridopyrazine derivatives
US5350755A (en) * 1986-12-05 1994-09-27 Schering Corporation Compounds and methods for treating hyperproliferative skin disease
US4740511A (en) * 1987-02-18 1988-04-26 Schering Corporation Method of treating hyperproliferative skin disease
CA1309658C (fr) * 1986-12-05 1992-11-03 David J. Blythin Compositions pharmaceutiques pour le traitement des maladies hyperproliferatives de la peau
EP0363353B1 (fr) * 1987-07-15 1992-07-22 Schering Corporation Benzazepines fusionnees
US4897487A (en) * 1988-04-06 1990-01-30 Schering Corporation Process for preparing intermediates for pharmaceutically useful bicyclic compounds
MX13270A (es) * 1987-10-05 1993-06-01 Pfizer Procedimiento para la preparacion de derivados de 4-aminopiridina
US5202440A (en) * 1987-10-05 1993-04-13 Pfizer Inc. Certain 9-amino-2-(or 4)-oxa 1,2,3,4-tetrahydro- or 1,2,3,4,5,6,7,8-octahydro-acridines
US4859669A (en) * 1987-12-23 1989-08-22 Schering Corporation Antiinflammatory and anti-hyperproliferative naphthyridin-4-ones
US5180823A (en) * 1988-04-06 1993-01-19 Schering Corporation Processes for preparing bicyclic compounds
US5079360A (en) * 1988-04-06 1992-01-07 Schering Corporation Processes for preparing bicyclic compounds and intermediates thereof
US4996212A (en) * 1989-12-21 1991-02-26 Schering Corporation Antiinflammatory and anti-hyperproliferative compounds
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP2671508B1 (fr) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Système pharma-informatique
CA2663377A1 (fr) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Traitement des troubles hepatiques par l'administration de conjugues de proteine associee au recepteur (rap)
JP2012512246A (ja) * 2008-12-17 2012-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング C環修飾型三環式ベンゾナフチリジノン・タンパク質キナーゼ阻害薬及びこれらの使用
HUE059078T2 (hu) 2009-02-20 2022-10-28 Enhanx Biopharm Inc Glutation-alapú hatóanyagszállító rendszer
JP2012526144A (ja) 2009-05-06 2012-10-25 ラボラトリー スキン ケア インコーポレイテッド 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB855022A (en) * 1957-08-06 1960-11-30 Geigy Ag J R Improvements in and relating to carbostyril derivatives
IT1054655B (it) * 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
JPS5854152B2 (ja) * 1976-03-25 1983-12-02 久光製薬株式会社 新規なナフチリジン誘導体
EP0005745B1 (fr) * 1978-05-26 1982-07-14 Gruppo Lepetit S.P.A. Pyrazolo (3,4-c) et thiazolo (5,4-c) isoquinolines, procédé pour leur préparation, ces composés utilisables comme agent anti-inflammatoire anti-anxiété et à action sur le SNC, et compositions pharmaceutiques les contenant
NL89090C (fr) * 1978-06-05
DE3368929D1 (de) * 1982-04-26 1987-02-12 Schering Corp 1,8-naphthyridine and 1,5,8-azanaphthyridine derivatives
US4452800A (en) * 1982-04-26 1984-06-05 Schering Corporation Salts of 3(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one and their use in treating chronic obstructive lung diseases

Also Published As

Publication number Publication date
DE3483064D1 (de) 1990-10-04
IL71960A (en) 1988-07-31
GR81552B (fr) 1984-12-11
DK160557C (da) 1991-09-09
AU559754B2 (en) 1987-03-19
AU2882484A (en) 1984-12-06
GB8413582D0 (en) 1984-07-04
NZ208310A (en) 1986-11-12
SG83890G (en) 1990-11-23
DK264784D0 (da) 1984-05-29
JPH0747590B2 (ja) 1995-05-24
US4680298A (en) 1987-07-14
GB2142013A (en) 1985-01-09
DK264784A (da) 1984-12-01
EP0127135B1 (fr) 1990-08-29
EP0127135A3 (en) 1985-08-21
JPS6034967A (ja) 1985-02-22
DK160557B (da) 1991-03-25
HK8092A (en) 1992-01-31
EP0127135A2 (fr) 1984-12-05
GB2142013B (en) 1987-01-21
IL71960A0 (en) 1984-09-30
CA1251208A (fr) 1989-03-14

Similar Documents

Publication Publication Date Title
PH22970A (en) Fused tricyclic derivatives of naphthyridinone, pyridone and quinoline and the corresponding thiones
PH21385A (en) 7-substituted quinoline and naphthyridine antibacterial agents
ZA848968B (en) 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL59667A (en) 4-amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives and their preparation
AU551596B2 (en) Naphthyridine and dinhydro quinoline derivatives
IL72601A0 (en) Dihydroimidazopyrrolopyridine,quinoline,thieno-and furo (2,3-b)pyridine,dihydrothieno-and furo(2,3-b)-pyridine,thieno-and furo(3,2-b)pyridine and dihydrothieno-and furo(3,2-b)pyridine herbicides and methods for the preparation thereof
PH18177A (en) Novel sesquihydrate of naphthyridine derivatives,and process for the preparation thereof
EP0145010A3 (en) Carbostyril derivatives
AU2896684A (en) (2-imidazolin-2-yl)thigno- and furo(2,3-b)and (3,2-b) pyridines
GB8329531D0 (en) Pyrazolopyridine cycloalkanones
GB2087390B (en) 5,6,7,8-tetrahydro-1,6-naphthyridine derivatives and their preparation
ZA8484B (en) Quinazolinone derivatives and process for the preparation thereof
ZA844083B (en) Fused tricyclic derivatives of naphthyridione,pyridone and quinolone and the corresponding thiones
GB2139621B (en) Pyridyl n-oxides
ZA895305B (en) Quinoline derivatives,their production and use
ZA855829B (en) Tricyclic quinoline derivatives
AU578055B2 (en) Imidazoquinolines and similar fused systems
GR81006B (en) Pyrimidoiso quinoline derivatives
GB2136799B (en) Quinoline derivatives
GB8423283D0 (en) Quinoline derivatives
ZA832928B (en) Dihydropyridine derivatives,their production and use
AU4188378A (en) Fused ring imidazo and pyrimidino-thiazole derivatives
ZA864416B (en) Polycyclic quinoline,naphthyridine and pyrazinopyridine derivatives
SG111094G (en) Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
DE3379403D1 (en) Fluoromethyl quinoline derivatives and their preparation